These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15583936)

  • 1. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
    Hüttmann A; Schirsafi K; Seeber S; Bojko P
    J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
    Orciuolo E; Buda G; Marturano E; Mauro E; Milone G; Cangialosi C; Di Renzo N; Pastore D; Specchia G; De Paolis MR; Mazza P; Pietrantuono G; Petrini M
    Leuk Res; 2011 Jul; 35(7):899-903. PubMed ID: 21134693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    Kahl C; Sayer HG; Hinke A; Freund M; Casper J
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):513-7. PubMed ID: 22198675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
    McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
    J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
    Ocheni S; Zabelina T; Bacher U; Ayuk F; Zander A; Kröger N
    Leuk Lymphoma; 2009 Apr; 50(4):612-8. PubMed ID: 19263295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
    Nolan L; Lorigan P; Chilton S; Newman J; Else R; Smith P; Linch D; Sweetenham JW; Johnson PW
    Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
    Marchesi F; Mengarelli A
    Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.